ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,821.80
0.68%
S&P ASX All Technology
3,088.00
0.64%
Brent Oil
79.835
1.62%
US Dollar vs AUD
1.50132
-0.08%
Bitcoin
71,364.00
0.40%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. GeoVax Labs Inc (GOVXW)

  7. GeoVax Labs Inc (GOVXW) News

GOVXW GeoVax Labs Inc

0.0375
0.00 (0.00%)
Last Updated: 00:11:20
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
GeoVax Labs Inc GOVXW NASDAQ Equity Warrant
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 0.0375 00:11:20
Open Price Low Price High Price Close Price Previous Close
0.0375
more quote information »

Recent News

Date Time Source Heading
25/5/202406:04EDGAR2Form 8-K - Current report
24/5/202406:07EDGAR2Form 8-K - Current report
22/5/202407:23EDGAR2Form 8-K - Current report
22/5/202402:32EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16/5/202406:03EDGAR2Form 8-K - Current report
15/5/202407:09EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/5/202407:09EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/5/202407:08EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/5/202407:07EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/5/202406:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/4/202403:30GLOBEGeoVax Presents Data on GEO-CM04S1, a Next Generation..
29/3/202400:00GLOBEGeoVax to Present Data on GEO-CM04S1, a Next Generation..
13/3/202400:00GLOBEGeoVax to Present at the 36th Annual Roth Conference
07/3/202401:00GLOBEGeoVax Achieves Milestone in Transition to Commercially..
01/3/202408:00GLOBEGeoVax Reports 2023 Year-End Financial Results and Provides..
23/2/202401:00GLOBEGeoVax to Report 2023 Financial Results and Provide..
20/2/202401:00GLOBEGeoVax to Present at the 2024 BIO CEO & Investor Conference
14/2/202401:00GLOBEGeoVax Announces Multiple Patent Issuances and Allowances
07/2/202401:00GLOBEGeoVax Reports Positive Interim Data From Phase 2 Clinical..
30/1/202401:00GLOBEGeoVax Announces 1-for-15 Reverse Stock Split to Regain..
09/1/202401:00GLOBEGeoVax Appoints Dr. Marc Pipas as Executive Medical..
05/1/202401:00GLOBEGeoVax Announces Gedeptin® Patient Enrollment Closure for..
04/1/202401:00GLOBEGeoVax Announces Issuance of Malaria Vaccine Patent
28/12/202301:00GLOBEGeoVax to Present at Biotech Showcase During J.P. Morgan..
20/12/202301:00GLOBEGeoVax Expands Rights Under NIH COVID-19 License to Include..
01/12/202308:30GLOBEGeoVax Hemorrhagic Fever Vaccine Data Presented at World..
30/11/202301:00GLOBEGeoVax to Participate in Upcoming December Investor Events
29/11/202301:00GLOBEGeoVax COVID-19 Vaccine Clinical Data Presented at World..
15/11/202301:00GLOBEProgress on GeoVax’s Universal Coronavirus Vaccine..
09/11/202308:00GLOBEGeoVax Reports Third Quarter 2023 Financial Results and..
01/11/202300:00GLOBEGeoVax to Report Third Quarter 2023 Financial Results and..
31/10/202300:00GLOBEGeoVax Commences Site Expansion for Phase 2 Trial of..
26/10/202300:00GLOBEGeoVax to Participate in Upcoming November Investor and..
25/10/202300:00GLOBEGeoVax Update: Clinical and Operational Progress Toward..
10/10/202300:00GLOBEGeoVax Receives Notice of Allowance for Marburg Vaccine..
06/10/202300:00GLOBEGeoVax Receives Notice of Allowance for HIV Vaccine Patent
27/9/202323:00GLOBEGeoVax to Participate in Upcoming October Investor and..
26/9/202323:00GLOBEGeoVax Secures Multi-Product License for ProBioGen's..
20/9/202323:00GLOBEGeoVax Next-Generation COVID-19 Vaccine Data Presented at..
19/9/202323:00GLOBEGeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent..
12/9/202323:00GLOBEGeoVax Presents Corporate Update at the H.C. Wainwright 25th..
11/9/202323:00GLOBEGeoVax Completes Enrollment of Phase 2 Trial for..
31/8/202323:00GLOBEGeoVax to Present at the H.C. Wainwright 25th Annual Global..
28/8/202323:00GLOBEGeoVax Receives Notice of Allowance for Malaria Vaccine..
10/8/202323:00GLOBEGeoVax Announces First Patients Vaccinated in Phase 2..
10/8/202306:00GLOBEGeoVax Reports 2023 Second Quarter Financial Results and..
26/7/202323:00GLOBEGeoVax to Report Second Quarter 2023 Financial Results and..
24/7/202323:00GLOBEGeoVax Announces Issuance of Ebola Vaccine Patent
20/7/202323:00GLOBEGeoVax Announces Initiation of Phase 2 Clinical Trial of..
10/7/202323:00GLOBEGeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS..

Your Recent History

NASDAQ
GOVXW
GeoVax Labs
BIT
P1WRN2
NLBNPIT1WRN2 20991231 25...
COIN
USCCUST
USC
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved